Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib plus R-CHOP in newly diagnosed high-risk DLBCL
NCT05887726Phase 2Unknown
- Sponsor
- Liaoning Medical Center
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Liaoning Medical Center. Primary endpoint: Complete Response Rate up to 2.5 years. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05887726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887726.